Who
Sandra Leung
Director
Company insider
Files Form 4 as: Director, Bausch Health Companies; EVP, General Counsel, Bristol-Myers Squibb; Director, Mead Johnson Nutrition Co.
In numbers
- Trades disclosed
- 436
- Buys
- 1
- Sells
- 10
- Bought
- $36K
- Sold
- $38.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 24 Feb 2006
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | $34K5,789 at $5.83 | filing |
| 30 Jun 2026filed 2 Jul 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | $34K6,845 at $4.93 | filing |
| 30 Jun 2026filed 2 Jul 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | $34K6,845 at $4.93 | filing |
| 22 May 2026filed 26 May 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —45,871 at $0.00 | filing |
| 22 May 2026filed 26 May 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —45,871 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | $32K5,946 at $5.40 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | $32K5,946 at $5.40 | filing |
| 31 Dec 2025filed 2 Jan 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —4,586 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —4,586 at $0.00 | filing |
| 30 Sep 2025filed 2 Oct 2025 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —3,673 at $0.00 | filing |
| 25 Jul 2025filed 29 Jul 2025 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —30,149 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,858 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,349 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,415 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —24,770 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —32,096 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —37,155 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —5,858 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —404 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $176K2,790 at $63.11 | filing |
News
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?BMY · aol.com · 22 Oct 2026Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 VolatilityBMY · fool.com · 22 Oct 2026AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?BMY · fool.com · 21 Oct 2026
0 headlines in the last 90 days name Sandra Leung; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.